POTENTIAL ANTI-CANCER AGENT INVESTIGATED AT NIST.
The method being pursued involves encapsulating these radionuclides with liposomes, which are spherical lipid vesicles that can mimic cellular membranes. Because lipids tend to be taken up by the liver, liposomes are an attractive candidate as a potential delivery mechanism for these radionucides. Using a protocol previously developed for the encapsulation of the imaging nuclide [Tc.sup.99m], the researchers have successfully encapsulated [At.sup.211] At [Bi.sub.212] [Bi.sub.211]using cyclotron-produced material from NIH in Bethesda. Further studies will focus on development of a quantitative analysis procedure, along with characterization of in vitro stability and radio-sensitivity. Long-term plans include expansion of the studies to other alpha-emitting radionuclides, such as the aforementioned [Bi.sup.212] and [Bi.213]Bi.
|Printer friendly Cite/link Email Feedback|
|Publication:||Journal of Research of the National Institute of Standards and Technology|
|Article Type:||Brief Article|
|Date:||Sep 1, 2000|
|Previous Article:||NIST NOMINATES CONFORMITY ASSESSMENT BODIES (CABs).|
|Next Article:||NIST MEASURES AN OPTICAL FREQUENCY IN A SINGLE MERCURY ION.|